Evidence map›Paper›PMID 28247183›Full record

ArticleMolecular diagnosis & therapy2017

The Challenges of Precision Medicine in COPD.

Mario Cazzola, Luigino Calzetta, Paola Rogliani, Maria Gabriella Matera

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diagnosis & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 45 citations in OpenAlex.

  1. Can Treatable Traits Be the Approach to Addressing the Complexity and Heterogeneity of COPD?International journal of chronic obstructive pulmonary disease · 2023
    Trial
  2. Review
  3. Review
  4. Article
  5. The future of inhalation therapy in chronic obstructive pulmonary disease.Current research in pharmacology and drug discovery · 2022
    Review
  6. Article
  7. Review
  8. Review
  9. Clinical Impact of Multidisciplinary Outpatient Care on Outcomes of Patients with COPD.International journal of chronic obstructive pulmonary disease · 2020
    Observational
  10. Article
  11. Review
  12. Precision medicine in COPD: where are we and where do we need to go?European respiratory review : an official journal of the European Respiratory Society · 2018
    Review
  13. Chronic obstructive pulmonary disease subpopulations and phenotyping.The Journal of allergy and clinical immunology · 2018
    Review
  14. Beyond Dual Bronchodilation - Triple Therapy, When and Why.International journal of chronic obstructive pulmonary disease
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Mario CazzolaChair of Respiratory Medicine, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy. mario.cazzola@uniroma2.it.
Luigino CalzettaChair of Respiratory Medicine, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
Paola RoglianiChair of Respiratory Medicine, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
Maria Gabriella MateraChair of Pharmacology, Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.
University of Rome Tor Vergata · ITUniversity of Campania "Luigi Vanvitelli" · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pheno-/endotyping chronic obstructive pulmonary disease (COPD) is really important because it provides patients with precise and personalized medicine. The central concept of precision medicine is to take individual variability into account when making management decisions. Precision medicine should ensure that patients get the right treatment at the right dose at the right time, with minimum harmful consequences and maximum efficacy. Ideally, we should search for genetic and molecular biomarker-based profiles. Given the clinical complexity of COPD, it seems likely that a panel of several biomarkers will be required to characterize pathogenetic factors and their course over time. The need for biomarkers to guide the clinical care of individuals with COPD and to enhance the possibilities of success in drug development is clear and urgent, but biomarker development is tremendously challenging and expensive, and translation of research efforts to date has been largely ineffective. Furthermore, the development of personalized treatments will require a much more detailed understanding of the clinical and biological heterogeneity of COPD. Therefore, we are still far from being able to apply precision medicine in COPD and the treatable traits and FEV

Indexed as

Adrenal Cortex HormonesAsthmaBiomarkersBronchodilator AgentsClinical Decision-MakingDisease ManagementHumansImmunoglobulin EOmalizumabPhenotypePrecision MedicinePulmonary Disease, Chronic ObstructivePulmonary EmphysemaTerminology as TopicAdrenal Cortex HormonesBiomarkersBronchodilator AgentsImmunoglobulin EOmalizumab

Identifiers

PMID28247183
OpenAlexW2593002735

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.